Maria C. Guerrero-Garcia

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

First-line dolutegravir/lamivudine penetrates lymph nodes and reduces HIV reservoirs comparably to triple therapy.

First-line dolutegravir/lamivudine penetrates lymph nodes and reduces HIV reservoirs comparably to triple therapy.

Journal: Research square
Published: June 12, 2026

Increases in total HIV-1 nucleic acid in whole blood precede plasma RNA rebound during pediatric analytical treatment interruption.

Increases in total HIV-1 nucleic acid in whole blood precede plasma RNA rebound during pediatric analytical treatment interruption.

Journal: AIDS (London, England)
Published: December 13, 2025

Increases in total HIV-1 nucleic acid in whole blood precede plasma rna rebound during paediatric analytical treatment interruption.

Increases in total HIV-1 nucleic acid in whole blood precede plasma rna rebound during paediatric analytical treatment interruption.

Journal: AIDS (London, England)
Published: December 13, 2025

Unveiling altered CD8 T-cell metabolism and homeostatic proliferation behind a low CD4/CD8 ratio in ART-suppressed HIV individuals with normal CD4 recovery.

Unveiling altered CD8 T-cell metabolism and homeostatic proliferation behind a low CD4/CD8 ratio in ART-suppressed HIV individuals with normal CD4 recovery.

Journal: Frontiers in immunology
Published: April 25, 2025

Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy.

Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy.

Journal: PLoS pathogens
Published: March 03, 2025

Author Correction: Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.

Author Correction: Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.

Journal: Nature medicine
Published: February 05, 2025

Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.

Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.

Journal: The Journal of infectious diseases
Published: May 23, 2024

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.

Journal: Med (New York, N.Y.)
Published: March 13, 2024

Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.

Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.

Journal: Nature medicine
Published: October 06, 2023

Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection.

Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection.

Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Published: June 19, 2023

Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors.

Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors.

Journal: AIDS (London, England)
Published: September 28, 2021

Erratum for Puertas et al., "VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies".

Erratum for Puertas et al., "VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies".

Journal: mBio
Published: September 28, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026